The National Institutes of Health (NIH) recommends neutralizing monoclonal antibody therapy for patients diagnosed with mild to moderate COVID-19 infection who do not currently require hospitalization but are at high risk for progression to severe infection and hospitalization or death.
There are currently 2 monoclonal antibody therapies authorized for emergency use by the FDA, REGEN-COV (Casirivimab plus Imdevimab) and Sotrovumab. Treatment should be started as soon as possible after the patient receives a positive SARS-CoV-2 test and within 10 days of symptom onset. As of July 30, 2021, the FDA has expanded the emergency use authorization of REGEN-COV for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are high risk of exposure to an infected individual in an institutional setting.
Monoclonal Antibody therapies are given as an intravenous infusion or subcutaneous injection at a dedicated infusion clinic only. You must have a referral and order from a provider in order to receive this medication. CHI Health has infusion centers available at multiple sites across Nebraska, Western Iowa, and Bismarck, ND.